|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anterior segment congestion of a right liver lobe graft in living-donor liver transplantation and strategy to prevent congestion显示文摘 | SungGyu Lee KwangMin Park Shin Hwang KiHoon Kim ChulSoo Ahn DukBok Moon JungWoo Joo SungHoon Cho KiBong Oh TaeYong Ha HyunSeong Yang KyuTaek Choi KyuSam Hwang EunJoo Lee YoungSang Lee HanJoo Lee YoungHwa Chung MyungHwan Kim SungKoo Lee DongJin Suh KyuBo S | 2003 | Journal of Hepato - Biliary - Pancreatic Surgery2003，，1： | 3 |
| 2 | Conditional survival in patients with gallbladder cancer显示文摘Background: Conditional survival(CS) has been established as a clinically relevant prognostic factor for cancer survivors, and the CS in gallbladder(GB) cancer has not yet been fully evaluated. In this study, we evaluated the cancerspecific CS rate and cancer-specific survival(CSS) rate in patients with GB cancer at multiple time points and investigated prognostic factors which affect cancer-specific CS rate to provide more accurate survival information.Methods: Between 2004 and 2013, a total of 9760 patients with GB cancer were identified from the Surveillance,Epidemiology, and End Results(SEER) data. The 3-year cancer-specific CS rate was calculated using the covariateadjusted survival function in the Cox model for each year since diagnosis, and the results were analyzed together with the adjusted CSS rates at the same time points. Cox proportional hazards regression was performed to ascertain the individual contribution of factors associated with CSS rate at diagnosis and cancer-specific CS rates at 1,3, and 5 years after diagnosis.Results: The adjusted 5-year CSS rate was 26.1 %. The adjusted 3-year cancer-specific CS rates at 1,2,3,4, and 5 years after diagnosis were 55.5,72.2,81.5,86.8, and 90.5%, respectively. At the time of diagnosis, age, race, histology, grade,T, N, and M categories, surgery, radiotherapy, insurance status, and marriage status were significant prognostic factors of CSS. Five years after diagnosis, however,T and M categories were significant prognostic factors for survivors(P = 0.007 and P = 0.009, respectively), whereas surgery and radiotherapy were not.Conclusions: T and M categories were significant prognostic factors even 5 years after the initial diagnosis, whereas local treatments at the time of diagnosis were not, suggesting that patients with GB cancer at high risks might need further adjuvant therapy after primary treatments. The combined analysis of CSS and cancer-specific CS rates offered more accurate survival information for patients who have already survived a certain period of time after diagnosis. | Yi-Jun Kim Kyubo Kim | 2017 | Chinese Journal of Cancer2017，36，12： | 3 |
| 3 | CD24 expression predicts distant metastasis in extrahepatic bile duct cancer显示文摘AIM: To evaluate the prognostic significance of CD24 expression in patients undergoing adjuvant chemoradiotherapy for extrahepatic bile duct (EHBD) cancer. METHODS: Eighty-four patients with EHBD cancer who underwent curative resection followed by adjuvant chemoradiotherapy were enrolled in this study. Postoperative radiotherapy was delivered to the tumor bed and regional lymph nodes up to a median of 40 Gy (range: 40-56 Gy). All patients also received fluoropyrimidine chemotherapy for radiosensitization during radiotherapy. CD24 expression was assessed with immunohistochemical staining on tissue microarray. Clinicopathologic factors as well as CD24 expression were evaluated in multivariate analysis for clinical outcomes including loco-regional recurrence, distant metastasisfree and overall survival. RESULTS: CD24 was expressed in 36 patients (42.9%). CD24 expression was associated with distant metastasis, but not with loco-regional recurrence nor with overall survival. The 5-year distant metastasis-free survival rates were 55.1% and 29.0% in patients with negative and positive expression, respectively (P=0.0100). On multivariate analysis incorporating N stage, histologic differentiation and CD24 expression, N stage was the only significant factor predicting distant metastasis-free survival (P=0.0089), while CD24 expression had borderline significance (P=0.0733). In subgroup analysis, CD24 expression was significantly associated with 5-year distant metastasis-free survival in node-positive patients (38.4% with negative expression vs 0% with positive expression, P=0.0110), but not in nodenegative patients (62.0% with negative expression vs 64.0% with positive expression,P=0.8599). CONCLUSION: CD24 expression was a significant predictor of distant metastasis for patients undergoing curative resection followed by adjuvant chemoradiotherapy especially for node-positive EHBD cancer. | Kyubo Kim Hye Sook Min Eui Kyu Chie Jin-Young Jang Sun Whe Kim Sae-Won Han Do-Youn Oh Seock-Ah Im Tae-You Kim Yung-Jue Bang Ja-June Jang Sung W Ha | 2013 | World Journal of Gastroenterology2013，19，9： | 2 |
| 4 | Concurrent radiotherapy with paclitaxel/ carhop latin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix显示文摘 | ME-YEON L HONG-GYUN W KYUBO K | 2007 | Gynecol Oncol2007，104，1： | 1 |
| 5 | Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix显示文摘 | Me-Yeon Lee Hong-Gyun Wu Kyubo Kim | 2007 | Gynecologic Oncology2007，104，1： | 1 |
| 6 | Behavior of open- and elosed-ender piles driven into sands显示文摘 | KYUBO Paik SALGADO Rodrigo LEE Junhwan | 2003 | Journal of Geotechnical and Geoenvironmental Engineering2003，，4： | 1 |
| 7 | Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix 显示文摘 | Me-Yeon Lee Hong-Gyun W Kyubo K | 2007 | Gvnecol Oncol2007，104，1： | 1 |
| 8 | Role of Adjuvant Chemoradiotherapy for Ampulla of Vater Cancer显示文摘 | Kyubo Kim Eui Kyu Chie Jin-Young Jang Sun Whe Kim Do-Youn Oh Seock-Ah Im Tae-You Kim Yung-Jue Bang Sung W. Ha | 2009 | International Journal of Radiation Oncology Biology Physics2009，，2： | 1 |
| 9 | Concurrent radiotherapy with paclitaxel / earbop latin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix显示文摘 | Me-Yeon L Hong-Gyun W Kyubo K | | 0，，01： | 1 |
| 10 | Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multiinstitutional analysis (KROG 19-04)显示文摘Objective:The effectiveness of adjuvant treatments for resected gallbladder carcinoma(GBC)has remained unclear due to lack of randomized controlled trials;thus,the aim of present study was to evaluate the role of adjuvant treatments,including chemoradiotherapy(CRT)and/or chemotherapy(CTx),in patients with resected GBC.Methods:A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional database.Of 733 patients,372(50.8%)did not receive adjuvant treatment,whereas 215(29.3%)and 146(19.9%)received adjuvant CTx and CRT,respectively.The locoregional recurrence-free survival(LRFS),recurrence-free survival(RFS),and overall survival(OS)of the adjuvant treatment groups were compared according to tumor stage(stage II vs.stage III–IV).Results:In stage II disease(n=381),the 5-year LRFS,RFS,and OS were not significantly different among the no-adjuvant therapy,CTx,and CRT groups,and positive resection margin,presence of perineural invasion,and Nx classification were consistently associated with worse LRFS,RFS,and OS in the multivariate analysis(P<0.05).For stage III–IV(n=352),the CRT group had significantly higher 5-year LRFS,RFS,and OS than the no-adjuvant therapy and CTx groups(67.8%,45.2%,and 56.9%;37.9%,28.8%,and 35.4%;and 45.0%,30.0%,and 45.7%,respectively)(P<0.05).Conclusions:CRT has value as adjuvant treatment for resected GBC with stage III–IV disease.Further study is needed for stage II disease with high-risk features. | Sung Uk Lee Jinsil Seong Tae Hyun Kim Jung Ho Im Woo Chul Kim Kyubo Kim Hae Jin Park Tae Gyu Kim Youngkyong Kim Bae Kwon Jeong Jin Hee Kim Byoung Hyuck Kim Taek-Keun Nam | 2022 | Cancer Biology & Medicine2022，19，6： | 0 |
| 11 | Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives显示文摘Extrahepatic bile duct cancer (EBDC) is a rare malignancy that involves neoplastic changes extending from both hepatic ducts to the common bile duct. The treatment of choice is surgical resection, but the predominant pattern of initial treatment failure is locoregional recurrence. Accordingly, adjuvant radiotherapy has been administered after surgical resection based on these rationales. At this time, there is minimal evidence supporting adjuvant radiotherapy, because there have been no phase III trials evaluating its benefit. Relatively small retrospective studies have tried to compare outcomes associated with EBDC treated with or without radiotherapy. We aimed to review studies investigating adjuvant radiotherapy for resected EBDC. Because less than onethird of EBDC cases are amenable to curative resection at diagnosis, other locoregional treatment modalities need to be considered, including radiotherapy. The next aim of this review was to summarize reports of definitive radiotherapy for unresectable EBDC. Patients with advanced EBDC often experience biliary obstruction, which can lead to jaundice and progress to death. Biliary stent insertion is an important palliative procedure, but stents are prone to occlusion after subsequent ingrowth of the EBDC. Radiotherapy can be effective for maintaining the patency of inserted stents. We also reviewed the benefit of palliative radiotherapy combined with the biliary stent insertion. Lastly, we discuss the existing gaps in the evidence supporting radiotherapy in the management of EBDC. | Taeryool Koo Hae Jin Park Kyubo Kim | 2019 | World Journal of Clinical Cases2019，7，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员